SA PRO
Free Account
Esperion Therapeutics, Inc.ESPRNASDAQ
LOADING
|||
OverviewChartsNewsFundamentalsEarningsAnalysts

Analyst Sentiment

Analysts are neutral — opinion is divided on direction.

Consensus Rating
Hold
22 analysts·High coverage
41%
Rating Distribution
Strong Buy
00%
Buy
941%
Hold
1150%
Sell
29%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see significant upside — consensus target 165% higher.

Bear Case
$9.00
+165%
Consensus
$9.00
+165%
Bull Case
$9.00
+165%
Price Range22 analysts
Low
Consensus
High
$9.00
$9.00
Current Target
Current Price
$3.39
Upside to Target
$5.61

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

2026E$0.14(6 analysts)
Actual
Estimate
Range (Low–High)
Stock Alarm Pro
Forward Growth Estimates (YoY)
FY2027
Rev+10.04%
EPS+67.42%
FY2028
Rev+36.01%
EPS+238.48%
FY2029
Rev+59.39%
EPS+96.18%

Earnings Surprises

Beat rate:67%(8/12 quarters)
Avg surprise:+58.1%
Beat
Miss
Inline
Estimate
Based on reported EPS vs consensus estimate.

Recent Analyst Actions

Nov 24, 2025Piper Sandler
Esperion initiated with an Overweight at Piper Sandler
Target:$9.00
+183.9%from $3.17
Sep 25, 2025Cantor Fitzgerald
Esperion price target raised to $9 from $7 at Cantor Fitzgerald
Target:$9.00
+251.6%from $2.56
Dec 17, 2024Cantor Fitzgerald
Esperion initiated with an Overweight at Cantor Fitzgerald
Target:$8.00
+163.2%from $3.04
May 4, 2022Needham
Esperion Therapeutics Rises on Upbeat Q1 Results
Target:$12.00
+83.8%from $6.53
May 4, 2021Wells Fargo
Esperion Stock Plummets On Wider Than Expected Q1 Earnings Loss; Analysts Move To Sidelines
Target:$20.00
-21.8%from $25.59

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance